Adding anti-CGRP monoclonal antibodies to standard treatment for chronic migraine with medication overuse headache significantly reduced headache frequency and painkiller use compared to conventional treatment alone.
p < 0.0001Anti-CGRP antibodies significantly reduced headache days and medication use compared to conventional treatment in chronic migraine patients
What the researchers found
In a study of 172 patients with chronic migraine and medication overuse headache, the group receiving anti-CGRP monoclonal antibodies added to conventional treatment (n=114) had a significantly greater reduction in both headache days and symptomatic medication intake at 3 months compared to the control group on conventional treatment alone (n=58), with p<0.0001.
Both groups showed improvement — indicating that the medication withdrawal and preventive treatment protocol helped on its own — but the addition of anti-CGRP antibodies provided a statistically significant additional benefit.
Why it matters
Medication overuse headache is one of the most challenging problems in headache medicine — patients take more painkillers to cope, which paradoxically worsens their headaches. CGRP (calcitonin gene-related peptide) is a key molecule in migraine pain signaling, and these results demonstrate that targeting this peptide with antibodies can help break the overuse cycle more effectively than standard treatments alone.
How the study worked
This was a cross-sectional, prospective, randomized, open-label study conducted in a real-world clinical setting. Two hundred patients with chronic migraine and medication overuse headache were enrolled. All patients underwent medication withdrawal and started preventive treatment. They were divided into a control group (n=58) receiving conventional treatment only and a treatment group (n=114) receiving anti-CGRP monoclonal antibodies in addition to conventional agents. Outcomes were measured at 3 months.
What this study cannot tell us
This was an open-label study, meaning both patients and doctors knew who was receiving the antibody treatment, which could introduce bias. The groups were unequal in size (114 vs. 58), and the specific anti-CGRP antibody used was not detailed in the abstract. The 3-month follow-up is relatively short for a chronic condition, and longer-term outcomes remain unknown. The study was conducted at a single tertiary care center, which may treat more severe cases than typical practice.
How to read the evidence
This is a prospective, randomized, open-label study with real-world comparison groups. The randomization strengthens the evidence, but the open-label design and unequal group sizes introduce potential bias. The statistically significant results (p<0.0001) are compelling despite these limitations.
When this study was published
Published in 2023, this study reflects current clinical practice with anti-CGRP monoclonal antibodies and provides recent real-world evidence for their use in medication overuse headache.
The bigger picture
Anti-CGRP monoclonal antibodies represent one of the first migraine treatments designed based on understanding the peptide biology of headache. This study adds real-world evidence that these therapies work not just for typical chronic migraine but specifically for the challenging subgroup of patients with medication overuse headache — a population often excluded from clinical trials. It supports expanding the use of peptide-targeted therapies to more complex headache presentations.
Questions still open
- Do the benefits of anti-CGRP antibodies in medication overuse headache persist beyond 3 months, or does efficacy change over time?
- Which specific anti-CGRP monoclonal antibody performs best in this population — erenumab, fremanezumab, or galcanezumab?
- Can anti-CGRP antibodies eventually allow patients to discontinue conventional preventive medications entirely?
Common questions
What is CGRP and why is it important in migraine?
What is medication overuse headache?
Read the original research
Monoclonal antibodies for chronic migraine and medication overuse headache: A real-world study.
Frontiers in neurology, 14, 1129439
Citation
Krymchantowski, Abouch V; Jevoux, Carla; Krymchantowski, Ana Gabriela; Silva-Néto, Raimundo Pereira. (2023). Monoclonal antibodies for chronic migraine and medication overuse headache: A real-world study.. Frontiers in neurology, 14, 1129439. https://doi.org/10.3389/fneur.2023.1129439